The ROSA robotic system allows surgeons to measure a patient’s specific anatomy to personalize the surgical approach.
Zimmer Biomet’s ROSA robotics system helps orthopedic surgeons be more accurate and precise
For many patients, orthopedic surgery is a quality-of-life saver. It can relieve pain and restore function to their bones and joints, helping keep them active—whether it’s running a 5k or simply getting dressed by themselves every morning. But highly complex surgeries such as joint replacements often are guided by surgeons’ experience and intuition. For instance, surgeons may know they want a certain incision to be made at a 40-degree angle, but when they make the cut, they judge the position with their eye.
Medical device company Zimmer Biomet recognized an opportunity to inject more accuracy, precision, and consistency into orthopedic surgery through the use of robotic tools. “Robotics bring objective measures to the table,” says Liane Teplitsky, president of global robotics and technology and data solutions at Zimmer Biomet. “It brings data that the surgeons can use to understand exactly why they’re doing what they’re doing.”
Zimmer Biomet created its ROSA robotic system to help orthopedic surgeons perform precise procedures and improve patient outcomes via data analytics. After being approved by the FDA for use in knee replacement surgeries in 2019, ROSA—which stands for “robotic surgical assistant”—gained approval for hip replacement surgeries in 2021. The introduction of robotic tools to improve the hip replacement process aims to deliver better results to the roughly 450,000 patients in the U.S. who have these surgeries every year. That’s a key reason why Zimmer Biomet earned a spot on Fast Company’s list of the world’s Most Innovative Companies.
Peter Coffaro is a growth-driven and strategic executive with over 25 years of progressive management success in the medical device industry. With a proven track record and recognized expertise, Peter has established himself as one of the top influencers in medical sales, as acknowledged by prestigious publications such as the World Journal of Orthopedics, Exponential Healthtech, and MedReps.com.
Throughout his career, Peter has accumulated 10 years of combined sales management experience, excelling in various roles including Director, General Manager, Distributor, and Vice President. He has worked for industry-leading orthopedic companies such as Zimmer, DePuy, and Stryker, solidifying his deep knowledge and network within the field.
Peter’s passion for innovation and emerging technologies led him to found OrthoFeed, an award-winning blog covering digital orthopedic news and emerging medical technologies. Through this platform, he stays at the forefront of the industry and contributes to the dissemination of valuable insights.
Peter is a three-time Hall of Fame award winner at Johnson and Johnson, demonstrating his exceptional contributions and impact on the organization. His expertise extends to areas such as organizational development, business development, sales management, digital marketing, and professional education.
Peter earned a B.S. degree in Biology and Chemistry from Northern Illinois University, further complementing his comprehensive understanding of the medical field.
With his wealth of experience, strategic mindset, and dedication to advancing healthcare, Peter Coffaro is a valuable asset and leader in the medical device industry.
(MEDTECHDIVE) – Now that Medicare has caught up to private payers and opening up coverage policies to ambulatory surgery centers, experts see the procedure migration to ASCs accelerating. […]
Under the terms of the agreements, Conformis will receive $14M up-front and up to an additional $16M in milestone payments for selling, licensing, and developing part of its intellectual property portfolio to Stryker in order to design, manufacture, and commercialize PSI for use in Stryker’s knee implant offerings, including the market-leading Triathlon Total Knee System. […]
A groundbreaking new treatment that uses 3D printed implants and that could bring relief to tens of thousands of knee osteoarthritis sufferers has received approval to be trialled in UK patients, following a virtual “in-silico” trial that demonstrated its safety. […]
Be the first to comment